Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study

Eri Muso, Masatoshi Mune, Tsutomu Hirano, Motoshi Hattori, Kenjiro Kimura, Tsuyoshi Watanabe, Hitoshi Yokoyama, Hiroshi Sato, Shunya Uchida, Takashi Wada, Tetsuo Shoji, Yukio Yuzawa, Tsukasa Takemura, Satoshi Sugiyama, Yoshiki Nishizawa, Satoru Ogahara, Noriaki Yorioka, Soichi Sakai, Yosuke Ogura, Susumu YukawaYasuhiko Iino, Enyu Imai, Seiichi Matsuo, Takao Saito

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: Hyperlipidemia is not merely a complication but a major exacerbating factor in longstanding nephrotic syndrome (NS). Low-density lipoprotein apheresis (LDL-A) has been reported to ameliorate dyslipidemia and induce rapid remission of NS. Several clinical studies have suggested the therapeutic efficacy of LDL-A, but the level of clinical evidence is insufficient. Therefore, a multicenter prospective study, POLARIS (Prospective Observational Survey on the Long-Term Effects of LDL Apheresis on Drug-Resistant Nephrotic Syndrome), was initiated in Japan. Method: Patients with drug-resistant NS were prospectively recruited into the study and treated with LDL-A in facilities that were registered in advance. In the POLARIS study design, the clinical data are to be followed up for 2 years. In the current study, we aimed at evaluating the short-term efficacy based on the treatment outcome of LDL-A immediately after completion of treatment. Results: Along with rapid improvement of hyperlipidemia, LDL-A significantly improved proteinuria and hypoproteinemia after treatment. More than half of the patients showed remission of NS based on the urinary protein level at the completion of LDL-A. The duration of NS before the start of treatment was significantly shorter in patients who responded to LDL-A. Conclusions: An analysis of patients registered in the POLARIS study indicated that LDL-A has short-term efficacy for drug-resistant NS. Rapid relief of dyslipidemia by LDL-A may provide early remission in about half of the NS patients who are resistant to conventional medication. Completion of the POLARIS study may reveal additional long-term effects of LDL-A in these patients.

Original languageEnglish
Pages (from-to)379-386
Number of pages8
JournalClinical and Experimental Nephrology
Volume19
Issue number3
DOIs
Publication statusPublished - 17-06-2015

Fingerprint

Blood Component Removal
Nephrotic Syndrome
LDL Lipoproteins
Pharmaceutical Preparations
Therapeutics
Dyslipidemias
Hyperlipidemias
Hypoproteinemia
Proteinuria
Multicenter Studies
Japan
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Physiology (medical)

Cite this

Muso, Eri ; Mune, Masatoshi ; Hirano, Tsutomu ; Hattori, Motoshi ; Kimura, Kenjiro ; Watanabe, Tsuyoshi ; Yokoyama, Hitoshi ; Sato, Hiroshi ; Uchida, Shunya ; Wada, Takashi ; Shoji, Tetsuo ; Yuzawa, Yukio ; Takemura, Tsukasa ; Sugiyama, Satoshi ; Nishizawa, Yoshiki ; Ogahara, Satoru ; Yorioka, Noriaki ; Sakai, Soichi ; Ogura, Yosuke ; Yukawa, Susumu ; Iino, Yasuhiko ; Imai, Enyu ; Matsuo, Seiichi ; Saito, Takao. / Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome : evidence from the short-term results from the POLARIS Study. In: Clinical and Experimental Nephrology. 2015 ; Vol. 19, No. 3. pp. 379-386.
@article{0b90f347ec7b43f1a5fed9f3fc4a72d8,
title = "Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study",
abstract = "Background: Hyperlipidemia is not merely a complication but a major exacerbating factor in longstanding nephrotic syndrome (NS). Low-density lipoprotein apheresis (LDL-A) has been reported to ameliorate dyslipidemia and induce rapid remission of NS. Several clinical studies have suggested the therapeutic efficacy of LDL-A, but the level of clinical evidence is insufficient. Therefore, a multicenter prospective study, POLARIS (Prospective Observational Survey on the Long-Term Effects of LDL Apheresis on Drug-Resistant Nephrotic Syndrome), was initiated in Japan. Method: Patients with drug-resistant NS were prospectively recruited into the study and treated with LDL-A in facilities that were registered in advance. In the POLARIS study design, the clinical data are to be followed up for 2 years. In the current study, we aimed at evaluating the short-term efficacy based on the treatment outcome of LDL-A immediately after completion of treatment. Results: Along with rapid improvement of hyperlipidemia, LDL-A significantly improved proteinuria and hypoproteinemia after treatment. More than half of the patients showed remission of NS based on the urinary protein level at the completion of LDL-A. The duration of NS before the start of treatment was significantly shorter in patients who responded to LDL-A. Conclusions: An analysis of patients registered in the POLARIS study indicated that LDL-A has short-term efficacy for drug-resistant NS. Rapid relief of dyslipidemia by LDL-A may provide early remission in about half of the NS patients who are resistant to conventional medication. Completion of the POLARIS study may reveal additional long-term effects of LDL-A in these patients.",
author = "Eri Muso and Masatoshi Mune and Tsutomu Hirano and Motoshi Hattori and Kenjiro Kimura and Tsuyoshi Watanabe and Hitoshi Yokoyama and Hiroshi Sato and Shunya Uchida and Takashi Wada and Tetsuo Shoji and Yukio Yuzawa and Tsukasa Takemura and Satoshi Sugiyama and Yoshiki Nishizawa and Satoru Ogahara and Noriaki Yorioka and Soichi Sakai and Yosuke Ogura and Susumu Yukawa and Yasuhiko Iino and Enyu Imai and Seiichi Matsuo and Takao Saito",
year = "2015",
month = "6",
day = "17",
doi = "10.1007/s10157-014-0996-8",
language = "English",
volume = "19",
pages = "379--386",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "3",

}

Muso, E, Mune, M, Hirano, T, Hattori, M, Kimura, K, Watanabe, T, Yokoyama, H, Sato, H, Uchida, S, Wada, T, Shoji, T, Yuzawa, Y, Takemura, T, Sugiyama, S, Nishizawa, Y, Ogahara, S, Yorioka, N, Sakai, S, Ogura, Y, Yukawa, S, Iino, Y, Imai, E, Matsuo, S & Saito, T 2015, 'Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study', Clinical and Experimental Nephrology, vol. 19, no. 3, pp. 379-386. https://doi.org/10.1007/s10157-014-0996-8

Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome : evidence from the short-term results from the POLARIS Study. / Muso, Eri; Mune, Masatoshi; Hirano, Tsutomu; Hattori, Motoshi; Kimura, Kenjiro; Watanabe, Tsuyoshi; Yokoyama, Hitoshi; Sato, Hiroshi; Uchida, Shunya; Wada, Takashi; Shoji, Tetsuo; Yuzawa, Yukio; Takemura, Tsukasa; Sugiyama, Satoshi; Nishizawa, Yoshiki; Ogahara, Satoru; Yorioka, Noriaki; Sakai, Soichi; Ogura, Yosuke; Yukawa, Susumu; Iino, Yasuhiko; Imai, Enyu; Matsuo, Seiichi; Saito, Takao.

In: Clinical and Experimental Nephrology, Vol. 19, No. 3, 17.06.2015, p. 379-386.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome

T2 - evidence from the short-term results from the POLARIS Study

AU - Muso, Eri

AU - Mune, Masatoshi

AU - Hirano, Tsutomu

AU - Hattori, Motoshi

AU - Kimura, Kenjiro

AU - Watanabe, Tsuyoshi

AU - Yokoyama, Hitoshi

AU - Sato, Hiroshi

AU - Uchida, Shunya

AU - Wada, Takashi

AU - Shoji, Tetsuo

AU - Yuzawa, Yukio

AU - Takemura, Tsukasa

AU - Sugiyama, Satoshi

AU - Nishizawa, Yoshiki

AU - Ogahara, Satoru

AU - Yorioka, Noriaki

AU - Sakai, Soichi

AU - Ogura, Yosuke

AU - Yukawa, Susumu

AU - Iino, Yasuhiko

AU - Imai, Enyu

AU - Matsuo, Seiichi

AU - Saito, Takao

PY - 2015/6/17

Y1 - 2015/6/17

N2 - Background: Hyperlipidemia is not merely a complication but a major exacerbating factor in longstanding nephrotic syndrome (NS). Low-density lipoprotein apheresis (LDL-A) has been reported to ameliorate dyslipidemia and induce rapid remission of NS. Several clinical studies have suggested the therapeutic efficacy of LDL-A, but the level of clinical evidence is insufficient. Therefore, a multicenter prospective study, POLARIS (Prospective Observational Survey on the Long-Term Effects of LDL Apheresis on Drug-Resistant Nephrotic Syndrome), was initiated in Japan. Method: Patients with drug-resistant NS were prospectively recruited into the study and treated with LDL-A in facilities that were registered in advance. In the POLARIS study design, the clinical data are to be followed up for 2 years. In the current study, we aimed at evaluating the short-term efficacy based on the treatment outcome of LDL-A immediately after completion of treatment. Results: Along with rapid improvement of hyperlipidemia, LDL-A significantly improved proteinuria and hypoproteinemia after treatment. More than half of the patients showed remission of NS based on the urinary protein level at the completion of LDL-A. The duration of NS before the start of treatment was significantly shorter in patients who responded to LDL-A. Conclusions: An analysis of patients registered in the POLARIS study indicated that LDL-A has short-term efficacy for drug-resistant NS. Rapid relief of dyslipidemia by LDL-A may provide early remission in about half of the NS patients who are resistant to conventional medication. Completion of the POLARIS study may reveal additional long-term effects of LDL-A in these patients.

AB - Background: Hyperlipidemia is not merely a complication but a major exacerbating factor in longstanding nephrotic syndrome (NS). Low-density lipoprotein apheresis (LDL-A) has been reported to ameliorate dyslipidemia and induce rapid remission of NS. Several clinical studies have suggested the therapeutic efficacy of LDL-A, but the level of clinical evidence is insufficient. Therefore, a multicenter prospective study, POLARIS (Prospective Observational Survey on the Long-Term Effects of LDL Apheresis on Drug-Resistant Nephrotic Syndrome), was initiated in Japan. Method: Patients with drug-resistant NS were prospectively recruited into the study and treated with LDL-A in facilities that were registered in advance. In the POLARIS study design, the clinical data are to be followed up for 2 years. In the current study, we aimed at evaluating the short-term efficacy based on the treatment outcome of LDL-A immediately after completion of treatment. Results: Along with rapid improvement of hyperlipidemia, LDL-A significantly improved proteinuria and hypoproteinemia after treatment. More than half of the patients showed remission of NS based on the urinary protein level at the completion of LDL-A. The duration of NS before the start of treatment was significantly shorter in patients who responded to LDL-A. Conclusions: An analysis of patients registered in the POLARIS study indicated that LDL-A has short-term efficacy for drug-resistant NS. Rapid relief of dyslipidemia by LDL-A may provide early remission in about half of the NS patients who are resistant to conventional medication. Completion of the POLARIS study may reveal additional long-term effects of LDL-A in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84931007441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931007441&partnerID=8YFLogxK

U2 - 10.1007/s10157-014-0996-8

DO - 10.1007/s10157-014-0996-8

M3 - Article

C2 - 24934117

AN - SCOPUS:84931007441

VL - 19

SP - 379

EP - 386

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 3

ER -